32,146 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Korea Investment CORP

Korea Investment CORP purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 32,146 shares of the medical equipment provider's stock, valued at approximately $2,767,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ZBH. DV Equities LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth $25,000. Tacita Capital Inc purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $26,000. Monetary Solutions Ltd purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at $30,000. Gen Wealth Partners Inc acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $31,000. Finally, Elevation Wealth Partners LLC boosted its position in shares of Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 229 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Down 0.1%

Shares of Zimmer Biomet stock opened at $100.89 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The company has a market cap of $19.24 billion, a P/E ratio of 24.55, a P/E/G ratio of 2.75 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average price of $92.90 and a 200 day moving average price of $91.14.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion for the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sang Yi sold 5,000 shares of the business's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company's stock, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.28% of the company's stock.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent analyst reports. BMO Capital Markets restated a "market perform" rating and set a $96.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, August 4th. Sanford C. Bernstein lifted their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. Zacks Research lowered shares of Zimmer Biomet from a "hold" rating to a "strong sell" rating in a report on Monday, July 27th. Finally, Citigroup decreased their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source